Navigation Links
Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
Date:2/28/2008

- Studies planned on the genetics of; - Asian populations with regard to risk associated in the development of

osteoporosis or cardiovascular disease - North American populations with regard to athletic/exercise performance

in response to nutritional products (nutrigenomics) - North American populations with regard to skin appearance (dermagenomics)

WALTHAM, Mass., Feb. 28 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) reported today that it has executed a new research agreement with Access Business Group International LLC (ABG), a subsidiary of Alticor Inc. The research agreement encompasses four main areas; osteoporosis, cardiovascular disease, nutrigenomics, and dermagenomics. Interleukin Genetics will be conducting various clinical studies, which shall be fully funded by Alticor. Studies will look to correlate single nucleotide polymorphic (SNPs) gene variations to the risk of osteoporosis or cardiovascular disease in Asian populations. Other studies will seek to identify genetic factors that influence athletic performance and skin appearance (wrinkles, elasticity, aging) for the purpose of developing products to enhance healthy aging.

Under the terms of the agreement, ABG will pay Interleukin Genetics $1.2 million during 2008 for the research. Approximately $800,000 of unspent funding from prior research agreements with Alticor shall also be credited against the costs incurred under this new agreement.

"This is our eighth research agreement with Alticor and we are pleased to continue to work with our partner on the development of genetic risk assessment tests in the field of osteoporosis and cardiovascular disease in new populations as well as
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
2. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
3. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
4. Interleukin Genetics Announces Management and Board Appointments
5. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
6. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
7. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service
8. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
9. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
10. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
11. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
(Date:5/23/2013)... 23, 2013  Saddleback Memorial Medical Center in ... first hospital on the West Coast to perform a ... option provides women with a state-of-the-art, minimally invasive approach ... Winter , M.D., a highly regarded ... director of minimally invasive surgery at Saddleback Memorial, led ...
(Date:5/23/2013)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... immune therapies for solid tumor cancers, announced today that ... Society Of Clinical Oncology (ASCO) meeting in ... immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... conference focused on clinical treatment of cancer, with attendance ...
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Oct. 27 eBioscience Corporation today announced that ... Bender MedSystems GmbH in an all cash transaction. ... high profile immunology and oncology products including the ... life sciences and diagnostics markets. , "Bender MedSystems ...
... Medivation, Inc. (Nasdaq: MDVN) today announced that it will ... October 27, to discuss partnering plans for MDV3100, Medivation,s investigational ... treatment of prostate cancer. , Teleconference/Webcast Details ... October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ...
... Champions Biotechnology, Inc. (OTC Bulletin ... aimed at accelerating the development and enhancing the value ... Biotech Oncology Research & Development, a Division of Janssen ... oncology therapeutic in Champions, Biomerk Tumorgraft(TM) platform. ...
Cached Biology Technology:eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 2eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 3Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 2Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 3
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... undergo surgery or harsh treatments because science fails ... forms of the disease. Researchers at Case Western ... developing technology that allows patients to safely choose ... or take drastic measures. , The project is ... of biomedical engineering at Case Western Reserve and ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... a cabbage-eating moth may one day provide a safer, target-specific ... , They compared the ability of the four best-characterized jumping ... and produce a desired change, such as making the cell ... piggyBac transposon was five to 10 times better than the ...
... the largest HIV/AIDS therapy studies conducted to date ... therapy more than doubles the risk of AIDS ... the Mailman School of Public Health and Harlem ... known as Strategies for Management of Anti-Retroviral Therapies, ...
... may be placing their unborn children at increased risk ... study of construction workers in the Netherlands, conducted in ... links low birth weight and birth defects to paternal, ... and cleansers. , The study, although preliminary in its ...
Cached Biology News:Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Study shows interruption of antiretroviral therapy increases risk of disease and death 2Study shows interruption of antiretroviral therapy increases risk of disease and death 3Solvent exposure linked to birth defects in babies of male painters 2
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Request Info...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
Biology Products: